信华生物完成数千万美元A轮系列融资；劲方医药通过聆讯，即将赴港上市｜医药早参

Group 1: Bayer's PRMT5 Inhibitor Approval - Bayer's small molecule PRMT5 inhibitor BAY 3713372 has received clinical trial approval in China for treating MTAP-DEL solid tumors [1] - The drug is an oral PRMT5 inhibitor, which selectively targets cancer cells and has a high safety profile [1] - Bayer has partnered with Puhe Pharmaceutical for global licensing, development, manufacturing, and commercialization of the product [1] Group 2: Eli Lilly's Orforglipron Clinical Trial Success - Eli Lilly announced positive top-line results from the Phase 3 clinical trial ATTAIN-2 for its GLP-1 receptor agonist orforglipron [2] - The trial showed significant weight loss and clinically meaningful reductions in A1C levels in obese or overweight adults with type 2 diabetes [2] - The oral administration of orforglipron offers a more convenient option compared to injectable GLP-1 receptor agonists, potentially reshaping treatment paradigms [2] Group 3: Ying Shi Bio's IPO Plans - Ying Shi Bio has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [3] - The company focuses on addressing the challenge of tumor resistance in cancer treatment and is in the late clinical stage [3] - Despite the potential of its core products, the company has not yet commercialized its products and continues to incur losses, indicating uncertainty in its IPO and profitability [3] Group 4: Xinhua Bio's Series A Financing - Xinhua Bio announced the completion of a multi-million dollar Series A financing round, with funding aimed at advancing its core pipeline into global clinical trials [4] - The financing was led by Xingze Capital and Sany Innovation Investment, with participation from existing shareholders [4] - The funds will accelerate research and development efforts, highlighting the company's potential in the field of tumor immunotherapy [4] Group 5: Jin Fang Pharma's Hong Kong Listing - Jin Fang Pharma has passed the hearing for its listing on the Hong Kong Stock Exchange [5] - The company, established in 2017, focuses on developing new treatment options for tumors and autoimmune/inflammatory diseases [5] - Jin Fang Pharma has established a product pipeline with eight candidate drugs, five of which are in clinical development [5]